Galderma to buy ZO Skin Health from Blackstone for $1.5B
What's the deal? Swiss skincare group GaldermaDealroom has a profile for this one. Try Dealroom → has agreed to acquire medical-grade skincare company ZO Skin HealthDealroom has a profile for this one. Try Dealroom → for about $1.5 billion, Reuters reported, citing two people familiar with the matter. ZO is currently owned by Blackstone. An announcement could come in the coming days.
Why now? Competition is intensifying for physician-distributed skincare brands backed by clinical research. The deal would strengthen Galderma's presence in the United States, a key market for these products.
What's the endgame? Galderma, in which L'Oréal holds a 20% stake, already owns CetaphilDealroom has a profile for this one. Try Dealroom → and Alastin Skincare, prescription acne treatments, the Dysport neurotoxin, and Restylane dermal fillers. Adding ZO extends its medical-grade skincare lineup.
What's the US play? The acquisition follows Galderma's August move to open its US and Latin America headquarters in Miami. Buying a US-based, physician-distributed brand deepens its footprint in the region.
The signal: Private equity owners like Blackstone are cashing out of clinically backed skincare as strategic buyers compete to consolidate the category.
Read more: finance.yahoo.com
Image credit: user1.codaz
